Quick Answer
Cytek Biosciences, Inc. reported Cash and Equivalents of $90.85 million for fiscal year 2025.
Cytek Biosciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $90.85M | -8.0% |
| 2024 | $98.72M | -41.0% |
| 2023 | $167.30M | -43.6% |
| 2022 | $296.60M | -18.7% |
| 2021 | $364.62M | +120.7% |
| 2020 | $165.23M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $93.28M | -42.5% | +23.6% |
| June 30, 2025 | $75.47M | -57.6% | -20.8% |
| March 31, 2025 | $95.30M | -43.5% | -3.5% |
| December 31, 2024 | $98.72M | -41.0% | -39.2% |
| September 30, 2024 | $162.27M | -0.8% | -8.8% |
| June 30, 2024 | $177.89M | +35.2% | +5.4% |
| March 31, 2024 | $168.79M | +30.4% | +0.9% |
| December 31, 2023 | $167.30M | -43.6% | +2.2% |
- Cytek Biosciences, Inc. showed a decrease of -8.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Cytek Biosciences, Inc.’s cash and equivalents has declined by 45.0% (from $165.23 million to $90.85 million).
- The most recent figure is from Cytek Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: